Maze Therapeutics and Alloy Therapeutics Form Broadwing Bio to Develop Antibody Therapies for Genetically Validated Targets in Ophthalmic DiseasesDownload PDF
SOUTH SAN FRANCISCO, CALIF., and LEXINGTON, MASS., Dec. 7, 2020 – Maze Therapeutics, a company focused on translating genetic insights into new medicines, and Alloy Therapeutics, a company developing platforms and services to enable drug discovery, today announced the formation of Broadwing Bio to develop targeted antibody therapies for the treatment of ophthalmic diseases. Broadwing Bio will advance programs directed to genetically validated ophthalmology targets identified using Maze’s human genetics and functional genomics platform, the COMPASS platform. Alloy Discovery Services will generate therapeutic candidates using Alloy’s broad suite of antibody discovery technologies, including the ATX-Gx™ mouse platform.
Under the terms of the agreement, Maze and Alloy will fund Broadwing Bio to rapidly advance its programs through preclinical and clinical development with the opportunity for independent financing and partnering. Maze and Alloy will retain certain rights to participate in the development and commercialization of products originating from Broadwing Bio. The company will be led by Andrew Peterson, Ph.D., founder and chief executive officer of Broadwing Bio.
This joint venture will allow us to pursue compelling Maze-identified targets…and develop highly differentiated therapies addressing unmet needs in ophthalmology
“We are very excited to partner with Alloy on the formation of Broadwing Bio, with a mission to advance therapeutics for ophthalmology indications,” said Jason Coloma, Ph.D., chief executive officer of Maze. “Maze is advancing a pipeline of programs based on genetic insights of disease, without restrictions on modality or therapeutic area. This joint venture will allow us to pursue compelling Maze-identified targets through a dedicated organization with the experience and focus to develop highly differentiated therapies addressing unmet needs in ophthalmology, while retaining significant financial participation and product rights.”
“Broadwing Bio is a great example of the high impact partnerships Alloy Discovery Services will conduct on a very select basis, where we can invest heavily in the success of the partnership,” said Errik Anderson, chief executive officer and founder of Alloy Therapeutics. “We are honored to be working with an incredible scientist-entrepreneur like Andy, in partnership with Maze’s team, to advance these exciting drug targets designated by Maze.”
Broadwing Bio has established a team of experienced leaders and scientific advisors, including
• Andrew Peterson, Ph.D., founder and chief executive officer, former senior director of molecular biology and metabolic disease at Genentech;
• Manuel Rivas, D.Phil, founder and scientific advisory board member, assistant professor in the Department of Biomedical Data Science at Stanford University;
• Tim Behrens, M.D., steering committee member and senior vice president, human genetics at Maze, former senior director of human genetics at Genentech;
• Piotr Bobrowicz, Ph.D., steering committee member and chief technology officer at Alloy, former chief scientific officer at Compass Therapeutics and director of antibody engineering and head of strain engineering and open innovation at Adimab;
• John Atkinson, M.D., scientific advisory board member, professor, Division of Biology and Biomedical Sciences, Washington University; and
• Dan Stamer, Ph.D., scientific advisory board member, Joseph A.C. Wadsworth Professor of Ophthalmology, Duke University School of Medicine.
There are a number of ophthalmic diseases for which effective therapeutic options are limited, but recent genetic insights provide avenues to change this situation
“There are a number of ophthalmic diseases for which effective therapeutic options are limited, but recent genetic insights provide avenues to change this situation,” said Dr. Peterson. “Broadwing Bio has the very unique opportunity to bring together the capabilities of two exceptional companies in order to develop novel treatments targeted at these diseases. I’m thrilled to join the company as CEO and look forward to building the Broadwing Bio team, while leveraging Maze and Alloy’s insights and experience in drug discovery in order to bring medicines to patients in need.”
About Maze Therapeutics
Maze Therapeutics is a biopharmaceutical company developing a broad portfolio of therapeutic candidates for a number of genetically defined diseases. Maze is focused on translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale human genetics data, cutting-edge functional genomics and an array of drug discovery approaches. The Maze COMPASS platform reveals modifier genes that confer protection and provides deeper understanding of the target biology and how these targets can be best targeted with drug therapies. Maze was launched in 2019 by Third Rock Ventures, with funding from ARCH Venture Partners, GV, Foresite Capital, Casdin Capital, Alexandria Venture Investments, City Hill and other undisclosed investors. Maze is based in South San Francisco. For more information please visit http://mazetx.com.
About Alloy Therapeutics
Alloy Therapeutics is a biotechnology company dedicated to empowering scientists in the relentless pursuit of making better medicines for all. To this end, Alloy seeks to democratize access to foundational drug discovery platforms and services to scientists worldwide. Alloy’s first platform, the ATX-Gx™ mouse platform, is a suite of transgenic mice designed for best-in-class in vivo discovery of fully human monoclonal antibodies. Alloy’s partners include academic scientists, small and medium biotech, and Fortune 50 biopharma. Founded in 2018 and privately funded by visionary investors, Alloy Therapeutics is headquartered in Boston, Massachusetts with European labs in Cambridge, UK. As a reflection of our irrational commitment to the scientific community, 100% of our revenue from platforms and services is reinvested in innovation and supporting access to innovation. To join the revolution, visit alloytx.com or schedule a 15-minute chat with our Founder and CEO at alloytx.com/ceo
Katie Engleman, 1AB
John D. Rosanelli
Vice President of Finance and Operations